Pacira BioSciences, Inc.

PCRX

Reporting person: DOMA Perpetual Capital Management LLC(fund)

DOMA Perpetual nominates 3 directors at Pacira, seeks CEO replacement and sale process

high confidence7.1% stake

Contest Strategydissident slate, solicitors, demands

IssuerPacira BioSciences, Inc. (PCRX)

Issuer solicitor—

Reporting personDOMA Perpetual Capital Management LLC (fund)

Dissident solicitor—

Stake2,777,794 phys / 0 synth7.1%

Dissident counsel—

Cost basis—

Meeting date—

Record date—

Primary demands

board representation
CEO replacement
formal sale process
strategic review

Advisors

No advisor data on record for this deal.

Sources

SEC Filing

DOMA Perpetual Capital Management LLC, holding approximately 7.1% of Pacira BioSciences, has nominated three director candidates and is calling for immediate replacement of CEO Frank Lee and a formal sale process of the company. The activist contends the stock has underperformed significantly (down 56% over a decade, 30% under current CEO), citing missed earnings guidance, lack of profitability, and excessive management compensation. DOMA argues the board has failed in oversight and the company should be sold to a larger entity that can better commercialize its EXPAREL asset.

Item id: fed30f4f-b82d-41ef-a7d5-0ccdbd14dec5 · ingested Apr 24, 2026